Skip to content
2000
Volume 1, Issue 1
  • ISSN: 2949-6632
  • E-ISSN: 2949-6640

Abstract

Approximately 20% of plant species naturally produce nitrogen-based secondary metabolites known as alkaloids. Many classes of alkaloids, including indoles, purines, quinolines, isoquinolines, tropanes, and imidazoles, are distinguished by their heterocyclic ring structures and metabolic antecedents. Their medical characteristics have been the subject of extensive research due to their therapeutic potential. Since cancer is the cause of ten million deaths globally each year, plant-based medications are good candidates for successful chemopreventive therapies. Secondary metabolites, such as alkaloids, have been shown to prevent cancer formation by regulating apoptosis, angiogenesis, microtubule assembly, and metabolic and signalling pathways. Well-known alkaloids have been effectively developed into anticancer drugs, including irinotecan, vindesine, vinblastine, vinorelbine, vincristine, topotecan, docetaxel, and paclitaxel. This study reviews the biological origins, metabolites, and side effects of marketed and experimental alkaloids used in cancer treatment.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cadmed/10.2174/0129496632397281250717055749
2025-08-05
2026-03-09

  • From This Site

    /content/journals/cadmed/10.2174/0129496632397281250717055749
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. KaurR.A.J. AroraS.A. Alkaloids-important therapeutic secondary metabolites of plant origin.J Crit Rev2015218
     [Google Scholar]
  2. DeyP. KunduA. KumarA. GuptaM. LeeB.M. BhaktaT. Analysis of alkaloids (indole alkaloids, isoquinoline alkaloids, tropane alkaloids).Recent Adv Nat Prod Anal.AmsterdamElsevier202050556710.1016/B978‑0‑12‑816455‑6.00015‑9
     [Google Scholar]
  3. HeinrichM. MahJ. AmirkiaV. Alkaloids used as medicines: Structural phytochemistry meets biodiversity-An update and forward look.Molecules2021267183610.3390/molecules26071836 33805869
     [Google Scholar]
  4. DebnathB. SinghW.S. DasM. Role of plant alkaloids on human health: A review of biological activities.Mater. Today Chem.20189567210.1016/j.mtchem.2018.05.001
     [Google Scholar]
  5. FanY. WangM. ZhangQ. Traditional uses, phytochemistry, pharmacology, toxicity and clinical application of traditional Chinese medicine Cynoglossum amabile: A review.Front. Pharmacol.202415132528310.3389/fphar.2024.1325283 38655180
     [Google Scholar]
  6. BhambhaniS. KondhareK.R. GiriA.P. Diversity in chemical structures and biological properties of plant alkaloids.Molecules20212611337410.3390/molecules26113374 34204857
     [Google Scholar]
  7. MattiuzziC. LippiG. Current cancer epidemiology.J. Epidemiol. Glob. Health20199421722210.2991/jegh.k.191008.001 31854162
     [Google Scholar]
  8. ShrihastiniV. MuthuramalingamP. AdarshanS. Plant-derived bioactive compounds, their anticancer effects and in silico approaches as an alternative target treatment strategy for breast cancer: An updated overview.Cancers 20211324622210.3390/cancers13246222 34944840
     [Google Scholar]
  9. UllahM.F. BhatS.H. HusainE. Cancer chemopreventive pharmacology of phytochemicals derived from plants of dietary and non-dietary origin: Implication for alternative and complementary approaches.Phytochem. Rev.201413481183310.1007/s11101‑014‑9341‑9
     [Google Scholar]
  10. RamakrishnaW. KumariA. RahmanN. MandaveP. Anticancer activities of plant secondary metabolites: Rice callus suspension culture as a new paradigm.Rice Sci.2021281133010.1016/j.rsci.2020.11.004
     [Google Scholar]
  11. MondalA. GandhiA. FimognariC. AtanasovA.G. BishayeeA. Alkaloids for cancer prevention and therapy: Current progress and future perspectives.Eur. J. Pharmacol.201985817247210.1016/j.ejphar.2019.172472 31228447
     [Google Scholar]
  12. HaqueM.U. FerdiousiN. SajonS.R. Anticancer agents derived from plant and dietary sources: A review.Int. J. Pharmacogn.201632556610.13040/IJPSR.0975‑8232.IJP.3(2).55‑66
     [Google Scholar]
  13. BatesD. EastmanA. Microtubule destabilising agents: Far more than just antimitotic anticancer drugs.Br. J. Clin. Pharmacol.201783225526810.1111/bcp.13126 27620987
     [Google Scholar]
  14. DhyaniP. QuispeC. SharmaE. Anticancer potential of alkaloids: A key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine.Cancer Cell Int.202222120610.1186/s12935‑022‑02624‑9 35655306
     [Google Scholar]
  15. HendriksH.R. LangdonS. BergerD.P. Comparative antitumour activity of vinblastine-isoleucinate and related vinca alkaloids in human tumour xenografts.Eur. J. Cancer1992284-576777310.1016/0959‑8049(92)90112‑F 1524896
     [Google Scholar]
  16. MannaK. DebnathB. SinghW.S. Major metabolites of certain marketed plant alkaloids.Front Nat Prod Chem2020612415010.2174/9789811448461120060006
     [Google Scholar]
  17. ŠkubníkJ. PavlíčkováV.S. RumlT. RimpelováS. Vincristine in combination therapy of cancer: Emerging trends in clinics.Biology 202110984910.3390/biology10090849 34571726
     [Google Scholar]
  18. NobleR.A. Inhibition of monocarboxylate transporter 1 by AZD3965 as a therapeutic approach in oncology.PhD Dissertation, Newcastle Universitr32017
     [Google Scholar]
  19. WittaS. CollinsK.P. RamirezD.A. MannheimerJ.D. WittenburgL.A. GustafsonD.L. Vinblastine pharmacokinetics in mouse, dog, and human in the context of a physiologically based model incorporating tissue‐specific drug binding, transport, and metabolism.Pharmacol. Res. Perspect.20231110105210.1002/prp2.1052 36631976
     [Google Scholar]
  20. EgbelakinA. FergusonM.J. MacGillE.A. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia.Pediatr. Blood Cancer201156336136710.1002/pbc.22845 21225912
     [Google Scholar]
  21. SisodiyaP.S. Plant derived anticancer agents: A review.Int J Res Dev Pharm Life Sci20132293308
     [Google Scholar]
  22. TaherM.A. NyeemM.A.B. BillahM.M. AhammedM.M. Vinca alkaloid-the second most used alkaloid for cancer treatment-A review.Int J Physiol Nutr Phys Educ20172723727
     [Google Scholar]
  23. WintonT. LivingstonR. JohnsonD. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.N. Engl. J. Med.2005352252589259710.1056/NEJMoa043623 15972865
     [Google Scholar]
  24. CapassoA. Vinorelbine in cancer therapy.Curr. Drug Targets20121381065107110.2174/138945012802009017 22594474
     [Google Scholar]
  25. ZhouA.S. TuckerJ.B. ScribanoC.M. Diverse microtubule-targeted anticancer agents kill cells by inducing chromosome missegregation on multipolar spindles.PLoS Biol.20232110300233910.1371/journal.pbio.3002339 37883329
     [Google Scholar]
  26. LevěqueD. JehlF. QuoixE. MonteilH. Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography.Xenobiotica199323111325133310.3109/00498259309059442 8310715
     [Google Scholar]
  27. de GraeveJ. van HeugenJ.C. ZorzaG. FahyJ. PuozzoC. Metabolism pathway of vinorelbine (Navelbine®) in human: Characterisation of the metabolites by HPLC–MS/MS.J. Pharm. Biomed. Anal.2008471475810.1016/j.jpba.2007.12.006 18242035
     [Google Scholar]
  28. KajitaJ. KuwabaraT. KobayashiH. KobayashiS. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes.Drug Metab. Dispos.20002891121112710.1016/S0090‑9556(24)15196‑3 10950859
     [Google Scholar]
  29. KumarS. SinghB. SinghR. Catharanthus roseus (L.) G. Don: A review of its ethnobotany, phytochemistry, ethnopharmacology and toxicities.J. Ethnopharmacol.202228411464710.1016/j.jep.2021.114647 34562562
     [Google Scholar]
  30. VatsT. BuchananG. MehtaP. A study of toxicity and comparative therapeutic efficacy of vindesine-prednisone vs. vincristine-prednisone in children with acute lymphoblastic leukemia in relapse.Invest. New Drugs199210323123410.1007/BF00877252 1428733
     [Google Scholar]
  31. HowardS.M. TheologidesA. SheppardJ.R. Comparative effects of vindesine, vinblastine, and vincristine on mitotic arrest and hormonal response of L1210 leukemia cells.Cancer Res.1980408 Pt 126952700 6248211
     [Google Scholar]
  32. RahmaniR. ZhouX.J. Pharmacokinetics and metabolism of vinca alkaloids.Cancer Surv.199317269281 8137344
     [Google Scholar]
  33. StoutN.L. Sabo WagnerS. Antineoplastic therapy side effects and polypharmacy in older adults with cancer.Top. Geriatr. Rehabil.2019351153010.1097/TGR.0000000000000212 31011239
     [Google Scholar]
  34. SwamyM.K. PurushothamB. SinniahU.R. Camptothecin: Occurrence, chemistry and mode of action.Bioactive Natural Products for Pharmaceutical Applications.ChamSpringer202131132710.1007/978‑3‑030‑54027‑2_9
     [Google Scholar]
  35. FujitaK. KubotaY. IshidaH. SasakiY. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.World J. Gastroenterol.20152143122341224810.3748/wjg.v21.i43.12234 26604633
     [Google Scholar]
  36. TalukdarA. KunduB. SarkarD. GoonS. MondalM.A. Topoisomerase I inhibitors: Challenges, progress and the road ahead.Eur. J. Med. Chem.202223611430410.1016/j.ejmech.2022.114304 35413618
     [Google Scholar]
  37. ParvezM.M. BasitA. JariwalaP.B. Quantitative investigation of irinotecan metabolism, transport, and gut microbiome activation.Drug Metab. Dispos.202149868369310.1124/dmd.121.000476 34074730
     [Google Scholar]
  38. MaM. McLeodH. Lessons learned from the irinotecan metabolic pathway.Curr. Med. Chem.2003101414910.2174/0929867033368619 12570720
     [Google Scholar]
  39. SinghR.K. RajpootN. Quantification of irinotecan (CPT-11) and its metabolite, SN-38, in rat plasma and bile samples: Application to pharmacokinetic studies.Lung Cancer20182223
     [Google Scholar]
  40. LorenceA. NesslerC.L. Camptothecin, over four decades of surprising findings.Phytochemistry200465202735274910.1016/j.phytochem.2004.09.001 15474560
     [Google Scholar]
  41. DiamondJ.R. GoffB. ForsterM.D. Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.Invest. New Drugs201735562763310.1007/s10637‑017‑0444‑1 28283779
     [Google Scholar]
  42. RosingH. van ZomerenD.M. DoyleE. BultA. BeijnenJ.H. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.Anticancer Drugs19989758759210.1097/00001813‑199808000‑00002 9773801
     [Google Scholar]
  43. MoscaL. IlariA. FaziF. AssarafY.G. ColottiG. Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.Drug Resist. Updat.20215410074210.1016/j.drup.2020.100742 33429249
     [Google Scholar]
  44. AbalM. AndreuJ. BarasoainI. Taxanes: Microtubule and centrosome targets, and cell cycle dependent mechanisms of action.Curr. Cancer Drug Targets20033319320310.2174/1568009033481967 12769688
     [Google Scholar]
  45. KavallarisM. Microtubules and resistance to tubulin-binding agents.Nat. Rev. Cancer201010319420410.1038/nrc2803 20147901
     [Google Scholar]
  46. LiebmannJ.E. CookJ.A. LipschultzC. TeagueD. FisherJ. MitchellJ.B. Cytotoxic studies of paclitaxel (Taxol®) in human tumour cell lines.Br. J. Cancer19936861104110910.1038/bjc.1993.488 7903152
     [Google Scholar]
  47. HuizingM.T. VermorkenJ.B. RosingH. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: A European Cancer Centre (ECC) trial.Ann. Oncol.19956769970410.1093/oxfordjournals.annonc.a059287 8664192
     [Google Scholar]
  48. HaoD.C. GeG.B. WangP. YangL. Impact of drug metabolism/pharmacokinetics and their relevance upon Taxus-based drug development.Curr. Drug Metab.2018191193095910.2174/1389200219666180523094635 29788882
     [Google Scholar]
  49. KircaK. KutlutürkanS. Symptoms experience and quality of life in the patients with breast cancer receiving the taxane class of drugs.Eur. J. Breast Health201814314815510.5152/ejbh.2018.3785 30123880
     [Google Scholar]
  50. MotykaS. JafernikK. EkiertH. Podophyllotoxin and its derivatives: Potential anticancer agents of natural origin in cancer chemotherapy.Biomed. Pharmacother.202315811414510.1016/j.biopha.2022.114145 36586242
     [Google Scholar]
  51. SkokŽ. ZidarN. KikeljD. IlašJ. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets.J. Med. Chem.202063388490410.1021/acs.jmedchem.9b00726 31592646
     [Google Scholar]
  52. WayengeraM. Identity of zinc finger nucleases with specificity to herpes simplex virus type II genomic DNA: Novel HSV-2 vaccine/therapy precursors.Theor. Biol. Med. Model.2011812310.1186/1742‑4682‑8‑23 21702927
     [Google Scholar]
  53. Del ReM. LatianoT. FidilioL. Unusual gastrointestinal and cutaneous toxicities by bleomycin, etoposide, and cisplatin: A case report with pharmacogenetic analysis to personalize treatment.EPMA J.201781697310.1007/s13167‑017‑0080‑z 28620445
     [Google Scholar]
  54. SinkuleJ.A. StewartC.F. CromW.R. MeltonE.T. DahlG.V. EvansW.E. Teniposide (VM26) disposition in children with leukemia.Cancer Res.198444312351237 6581866
     [Google Scholar]
  55. KamP.C.A. LiewS. Traditional Chinese herbal medicine and anaesthesia.Anaesthesia200257111083108910.1046/j.1365‑2044.2002.02823.x 12392455
     [Google Scholar]
  56. KumaraP.M. SoujanyaK.N. RavikanthG. VasudevaR. GaneshaiahK.N. ShaankerR.U. Rohitukine, a chromone alkaloid and a precursor of flavopiridol, is produced by endophytic fungi isolated from Dysoxylum binectariferum Hook.f and Amoora rohituka (Roxb). Wight & Arn.Phytomedicine201421454154610.1016/j.phymed.2013.09.019 24215673
     [Google Scholar]
  57. NitulescuG. Van De VenterM. NitulescuG. The Akt pathway in oncology therapy and beyond (Review).Int. J. Oncol.201853623193110.3892/ijo.2018.4597 30334567
     [Google Scholar]
  58. VarshneyS. ShankarK. BegM. Rohitukine inhibits in vitro adipogenesis arresting mitotic clonal expansion and improves dyslipidemia in vivo.J. Lipid Res.20145561019103210.1194/jlr.M039925 24646949
     [Google Scholar]
  59. ManiD.N. ShuklaS. ShuklaY.N. Medicinal plant-derived therapeutics for treatment of neoplasms in modern and traditional systems of medicine.Curr. Res. Med. Aromat. Plants202042202012910.62029/jmaps.v42i1.Mani
     [Google Scholar]
  60. PommierY. Topoisomerase I inhibitors: Camptothecins and beyond.Nat. Rev. Cancer200661078980210.1038/nrc1977 16990856
     [Google Scholar]
  61. PlatzerP. ThalhammerT. HamiltonG. Metabolism of camptothecin, a potent topoisomerase I inhibitor, in the isolated perfused rat liver.Cancer Chemother. Pharmacol.2000451505410.1007/PL00006742 10647501
     [Google Scholar]
  62. VendittoV.J. SimanekE.E. Cancer therapies utilizing the camptothecins: A review of the in vivo literature.Mol. Pharm.20107230734910.1021/mp900243b 20108971
     [Google Scholar]
  63. HuangL. XueZ. Cephalotaxus alkaloids.The Alkaloids: Chemistry and PharmacologyNew YorkAcademic Press19842315722610.1016/S0099‑9598(08)60071‑1
     [Google Scholar]
  64. LucasD.M. StillP.C. PérezL.B. GreverM.R. KinghornA.D. Potential of plant-derived natural products in the treatment of leukemia and lymphoma.Curr. Drug Targets201011781282210.2174/138945010791320809 20370646
     [Google Scholar]
  65. NovotnyL. Al-TannakN.F. HunakovaL. Protein synthesis inhibitors of natural origin for CML therapy: Semisynthetic homoharringtonine (Omacetaxine mepesuccinate).Neoplasma201663449550310.4149/neo_2016_401 27268912
     [Google Scholar]
  66. ChenX. TangY. ChenJ. Homoharringtonine is a safe and effective substitute for anthracyclines in children younger than 2 years old with acute myeloid leukemia.Front. Med.201913337838710.1007/s11684‑018‑0658‑4 30635781
     [Google Scholar]
  67. SonN.T. Genus Acronychia: An extensive review on phytochemistry and pharmacological activities.Mini Rev. Org. Chem.202320881884110.2174/1570193X20666221026162904
     [Google Scholar]
  68. NguyenQ.C. NguyenT.T. YougniaR. Acronycine derivatives: A promising series of anticancer agents.Anticancer. Agents Med. Chem.20099780481510.2174/187152009789056921 19594412
     [Google Scholar]
  69. ChenA.H. LiuQ.L. MaY.L. A new monoterpenoid indole alkaloid from Ochrosia elliptica.Nat. Prod. Res.201731131490149410.1080/14786419.2016.1277349 28068850
     [Google Scholar]
  70. StiborovaM. RupertovaM. SchmeiserH.H. FreiE. Molecular mechanisms of antineoplastic action of an anticancer drug ellipticine.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.20061501132310.5507/bp.2006.002 16936898
     [Google Scholar]
  71. StiborováM. FreiE. Ellipticines as DNA-targeted chemotherapeutics.Curr. Med. Chem.201421557559110.2174/09298673113206660272 24059226
     [Google Scholar]
  72. StiborovaM. MoserovaM. MrazovaB. KotrbovaV. FreiE. Role of cytochromes P450 and peroxidases in metabolism of the anticancer drug ellipticine: Additional evidence of their contribution to ellipticine activation in rat liver, lung and kidney.Neuroendocrinol. Lett.201031Suppl. 22635 21187821
     [Google Scholar]
  73. KizekR. AdamV. HrabetaJ. Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances.Pharmacol. Ther.20121331263910.1016/j.pharmthera.2011.07.006 21839775
     [Google Scholar]
  74. CagirA. JonesS.H. GaoR. EisenhauerB.M. HechtS.M. A naturally occurring human DNA topoisomerase I poison.J. Am. Chem. Soc.200312545136281362910.1021/ja0368857 14599178
     [Google Scholar]
  75. LiX.W. FangS.J. LiY.Z. Design and synthesis of luotonin A-derived topoisomerase targeting scaffold with potent antitumor effect and low genotoxicity.Bioorg. Chem.202414310701510.1016/j.bioorg.2023.107015 38086241
     [Google Scholar]
  76. LeeS. LeeJ. JahngY. JeongT.C. KimD.H. Characterization of] in vitro metabolites of luotonin A in human liver microsomes using electrospray/tandem mass spectrometry.Xenobiotica201343652753310.3109/00498254.2012.746486 23256623
     [Google Scholar]
  77. IsahT. Anticancer alkaloids from trees: Development into drugs.Pharmacogn. Rev.20161020909910.4103/0973‑7847.194047 28082790
     [Google Scholar]
  78. YouL. YangC. DuY. A systematic review of the pharmacology, toxicology and pharmacokinetics of matrine.Front. Pharmacol.2020110106710.3389/fphar.2020.01067 33041782
     [Google Scholar]
  79. DubeyK.K. KumarP. LabrouN.E. ShuklaP. Biotherapeutic potential and mechanisms of action of colchicine.Crit. Rev. Biotechnol.20173781038104710.1080/07388551.2017.1303804 28436240
     [Google Scholar]
  80. KallinichT. HaffnerD. NiehuesT. Colchicine use in children and adolescents with familial Mediterranean fever: Literature review and consensus statement.Pediatrics20071192e474e48310.1542/peds.2006‑1434 17242135
     [Google Scholar]
  81. ChoJ.H. JooY.H. ShinE.Y. ParkE.J. KimM.S. Anticancer effects of colchicine on hypopharyngeal cancer.Anticancer Res.201737116269628010.21873/anticanres.12078 29061810
     [Google Scholar]
  82. EmaraR. TahaN. MandourA.E.W. LebdaM. RashedM. MenshawyM. Biochemical and histopathological effects of colchicine and Moringa oleifera on thioacetamide-induced liver fibrosis in rats.Egypt. Acad. J. Biol. Sci. B Zool.202113126527810.21608/eajbsz.2021.180913
     [Google Scholar]
  83. AnandU. DeyA. ChandelA.K.S. Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics.Genes Dis.20231041367140110.1016/j.gendis.2022.02.007 37397557
     [Google Scholar]
  84. DyshlovoyS.A. KauneM. HauschildJ. Efficacy and mechanism of action of marine alkaloid 3,10-dibromofascaplysin in drug-resistant prostate cancer cells.Mar. Drugs2020181260910.3390/md18120609 33271756
     [Google Scholar]
  85. SpirinP. ShyrokovaE. LebedevT. Cytotoxic marine alkaloid 3,10-dibromofascaplysin induces apoptosis and synergizes with cytarabine resulting in leukemia cell death.Mar. Drugs202119948910.3390/md19090489 34564151
     [Google Scholar]
  86. WuL. YeK. JiangS. ZhouG. Marine power on cancer: Drugs, lead compounds, and mechanisms.Mar. Drugs202119948810.3390/md19090488 34564150
     [Google Scholar]
  87. CesakO. VostalovaJ. VidlarA. BastlovaP. StudentV. Carnosine and beta-alanine supplementation in human medicine: Narrative review and critical assessment.Nutrients2023157177010.3390/nu15071770 37049610
     [Google Scholar]
  88. LucenaA.M.M. SouzaC.R.M. JalesJ.T. The bisindole alkaloid cauldron, from seaweeds of the genus Caulerpa, attenuated colon damage in murine colitis model.Mar. Drugs201816931810.3390/md16090318 30205459
     [Google Scholar]
  89. DissanayakeI.H. BandaranayakeU. KeerthirathnaL.R. Integration of in vitro and in-silico analysis of Caulerpa racemosa against antioxidant, antidiabetic, and anticancer activities.Sci. Rep.20221212084810.1038/s41598‑022‑24021‑y 36460661
     [Google Scholar]
  90. QinR. YouF.M. ZhaoQ. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: From molecular mechanisms to potential therapeutic targets.J. Hematol. Oncol.202215113310.1186/s13045‑022‑01350‑z 36104717
     [Google Scholar]
  91. YuL. ShenN. RenJ. XinH. CuiY. Resource distribution, pharmacological activity, toxicology and clinical drugs of β-Carboline alkaloids: An updated and systematic review.Fitoterapia202518010632610.1016/j.fitote.2024.106326 39645053
     [Google Scholar]
  92. WangY. WangH. ZhangL. Subchronic toxicity and concomitant toxicokinetics of long-term oral administration of total alkaloid extracts from seeds of Peganum harmala Linn: A 28-day study in rats.J. Ethnopharmacol.201923811186610.1016/j.jep.2019.111866 30970283
     [Google Scholar]
  93. LimaG. SoaresC. TeixeiraM. Castelo-BrancoM. Psychedelic research, assisted therapy and the role of the anaesthetist: A review and insights for experimental and clinical practices.Br. J. Clin. Pharmacol.202490123119313410.1111/bcp.16264 39380091
     [Google Scholar]
  94. BennyF. KumarS. JayanJ. Review of β‐carboline and its derivatives as selective MAO‐A inhibitors.Arch Pharm20233567230009110.1002/ardp.202300091 37021551
     [Google Scholar]
  95. SahooC.R. PaidesettyS.K. PadhyR.N. Norharmane as a potential chemical entity for development of anticancer drugs.Eur. J. Med. Chem.201916275276410.1016/j.ejmech.2018.11.024 30496990
     [Google Scholar]
  96. HuY. YuX. YangL. Research progress on the antitumor effects of harmine.Front. Oncol.202414138214210.3389/fonc.2024.1382142 38590646
     [Google Scholar]
  97. WrońskaA.K. BoguśM.I. KaczmarekA. KazekM. Harman and norharman, metabolites of entomopathogenic fungus Conidiobolus coronatus (Entomopthorales), disorganize development of Galleria mellonella (Lepidoptera) and affect serotonin-regulating enzymes.PLoS One20181310020482810.1371/journal.pone.0204828 30281642
     [Google Scholar]
  98. GoodwinA.K. Lantz-McPeakS.M. RobinsonB.L. LawC.D. AliS.F. FergusonS.A. Effects of adolescent treatment with nicotine, harmane, or norharmane in male Sprague–Dawley rats.Neurotoxicol. Teratol.20154747253510.1016/j.ntt.2014.10.005 25450662
     [Google Scholar]
  99. ZhangC.X. XiJ. ZhaoT.P. MaY.X. WangX.D. β -carbolines norharman and harman in vegetable oils in China.Food Addit. Contam. Part B Surveill.202013319319910.1080/19393210.2020.1759701 32364007
     [Google Scholar]
/content/journals/cadmed/10.2174/0129496632397281250717055749
Loading
Role of Alkaloidal Drugs in Cancer Treatment: A Review
Curr. Adv. Med. 1, E29496632397281 (2025); https://doi.org/10.2174/0129496632397281250717055749
/content/journals/cadmed/10.2174/0129496632397281250717055749
/content/journals/cadmed/10.2174/0129496632397281250717055749
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Alkaloids; cancer; chemopreventive therapies; experimental alkaloids; major metabolites; marketed alkaloids
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test